Supplementary Table 2.
Baseline clinical, angiographic, and procedural characteristics of patients enrolled among trials included in the meta–analysis
| Characteristics | REAL/ZEST–LATE‡ | RESET‡ | OPTIMIZE‡ | DAPT | EXCELLENT‡ | SECURITY | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorter | Longer | Shorter | Longer | Shorter | Longer | Shorter | Longer | Shorter | Longer | Shorter | Longer | |
| Age (years) | 61.9 | 62.0 | 62.4 | 62.4 | 61.3 | 61.9 | 62.8 | 62.5 | 63.0 | 62.4 | 65.5 | 66.7 |
| Female (%) | 30.6 | 30.0 | 35.1 | 37.1 | 36.5 | 36.9 | 29.2 | 31.0 | 34.9 | 36.1 | 28.2 | 26.0 |
| DM (%) | 27.1‡ | 25.1‡ | 30.1‡ | 28.8 | 35.4‡ | 35.3‡ | 100.0 | 100.0 | 37.7‡ | 38.6‡ | 100 | 100 |
| Type 1 (%) | – | – | – | – | 10.2 | 10.4 | 28.1 | 29.3 | – | – | 21.4 | 19.7 |
| Type 2 (%) | – | – | – | – | 25.2 | 24.9 | 71.9 | 70.9 | – | – | 78.6 | 80.3 |
| Hypertension (%) | 56.9 | 57.1 | 62.6 | 61.4 | 86.4 | 88.2 | 88.6 | 87.2 | 72.7 | 73.8 | 82.5 | 80.3 |
| Dyslipidemia (%) | 43.5 | 43.2 | 58.2 | 59.9 | 63.2 | 63.7 | – | – | 75.2 | 76.3 | 69.4 | 70.9 |
| Current smoking (%) | 32.1 | 29.8 | 25.0 | 22.8 | 18.6 | 17.3 | 21.4 | 20.1 | 27.4 | 25.8 | 18.9 | 20.2 |
| Prior MI (%) | 3.3 | 3.8 | 1.8 | 1.6 | 34.6 | 34.8 | 24.8 | 23.2 | 6.5 | 3.7 | 23.8 | 17.1 |
| Prior PCI (%) | 11.8 | 13.0 | 3.7 | 3.0 | 20.9 | 19.1 | 34.1 | 35.6 | 9.3 | 8.6 | 22.8 | 17.0 |
| Prior CABG (%) | – | – | 0.2 | 0.6 | 7.1 | 8.2 | 16.4 | 15.2 | 1.5 | 1.0 | 5.8 | 7.2 |
| Prior stroke (%) | 3.3 | 4.3 | 0.0 | 0.0 | 2.5 | 2.5 | 4.2 | 5.3 | 6.5 | 6.7 | – | – |
| Peripheral arterial disease (%) | – | – | 0.0 | 0.0 | 2.8 | 3.0 | 8.6 | 8.6 | – | – | – | – |
| Heart failure (%) | – | – | 10.0 | 11.8 | 4.3 | 4.2 | 8.2 | 7.5 | 0.6 | 0.7 | – | – |
| Renal insufficiency (%) | – | – | –§ | –§ | 7.4 | 5.8 | 7.2 | 6.2 | 0.8 | 1.2 | –§ | –§ |
| LVEF (%) | 59.7 | 59.2 | 64.3 | 63.9 | – | – | – | – | 61.0 | 61.4 | 55.8 | 55.7 |
| ACS (%) | 21.2 | 22.1 | 14.6 | 13.8 | 31.6* | 32.3* | 21.4 | 22.3 | 51.1† | 52.0† | 35.9 | 32.3 |
| Therapy at discharge | ||||||||||||
| Aspirin + clopidogrel | 99.9 | 99.7 | 100.0 | 100.0 | 100.0 | 100.0 | 64.6 | 68.3 | 100.0 | 100.0 | 99.0 | 98.7 |
| Aspirin + prasugrel | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35.4 | 31.7 | 0.0 | 0.0 | 0.5 | 0.0 |
| Multivessel disease | 48.1 | 48.0 | 42.2 | 42.9 | – | – | – | – | 51.9 | 52.0 | 54.3 | 47.8 |
| Bifurcation | 12.5 | 12.1 | 0.0 | 0.0 | 14.7 | 14.9 | – | – | 10.2 | 11.4 | 10.7 | 12.1 |
| Stents implanted | ||||||||||||
| Per patient | 1.6 | 1.8 | 1.3 | 1.5 | 1.6 | 1.6 | 11.5 | 1.4 | 1.6 | 1.6 | 1.6 | 1.6 |
| Per lesion | 1.2 | 1.3 | 1.0 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 |
| Stent length per lesion (mm) | 30.9 | 31.8 | 22.7 | 22.9 | 20.4 | 20.4 | 19.2 | 18.1 | 27.8 | 28.3 | 19.2 | 19.3 |
| Treated vessel | ||||||||||||
| Left main coronary | 2.4 | 2.9 | 0.0 | 0.0 | 1.2 | 1.5 | 0.8 | 0.9 | 0.0 | 0.0 | 0.0 | 0.0 |
| Left anterior descending | 49.9 | 48.7 | 52.7 | 53.6 | 47.9 | 46.6 | 37.4 | 38.2 | 49.6 | 50.4 | 39.0 | 41.0 |
| Left circumflex | 18.1 | 19.9 | 21.3 | 19.2 | 23.4 | 24.3 | 24.3 | 24.1 | 22.0 | 21.7 | 19.0 | 18.0 |
| Right coronary | 29.6 | 28.5 | 67.6 | 69.2 | 27.6 | 27.7 | 33.0 | 33.2 | 28.3 | 27.9 | 32.0 | 28.0 |
| Stent type | ||||||||||||
| First-generation | 80.2 | 80.9 | 0.0 | 28.5 | 0.0 | 0 | 36.2 | 35.5 | 74.8 | 74.8 | 0.0 | 0.0 |
| Second-generation | 18.8 | 18.7 | 100.0 | 71.5 | 100.0 | 100.0 | 53.3 | 54.0 | 25.2 | 25.2 | 100.0 | 100.0 |
*Low–risk ACS (UA or MI <30 days); †Low–risk ACS (MI <72 h was excluded); ‡The characteristics of patients were extracted from the overall population but not only diabetic patients; §Patients with serum creatinine >2.0 mg/dl were not included in the study. ACS: Acute coronary syndrome; CABG: Coronary artery bypass grafting; DES: Drug–eluting stent; LVEF: Left ventricular ejection fraction; MI: Myocardial infarction; PCI: Percutaneous coronary intervention; –: Could not be calculated; DAPT: Dual antiplatelet therapy; DM: Diabetes mellitus; UA: Unstable angina.